HAE
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Haemonetics Corporation is a medical technology company that develops and sells devices, disposables, and software for plasma collection, blood center operations, and hospital care. The company operates through three segments: Plasma, Blood Center, and Hospital. The Plasma segment provides automated apheresis systems and donor management software for source plasma collection centers, serving biopharmaceutical companies such as Grifols, Octapharma, Takeda, and CSL. The Blood Center segment supplies collection and processing equipment for blood banks and centers, including the American Red Cross. The Hospital segment offers interventional technologies, including vascular closure systems and sensor-guided tools, as well as blood management technologies for hemostasis, cell salvage, and transfusion. Key products include the NexSys PCS plasma collection system, NexLynk DMS software, Cell Saver systems, TEG hemostasis analyzers, and the VASCADE vascular closure family. The company serves customers globally, with a significant focus on the United States for plasma collection operations.

Summarised from the company's own disclosures, fiscal year ended May 2026

Industry Medical Devices Homepage haemonetics.com
Sector Healthcare IR page haemonetics.com
Tags
plasma collection, apheresis, blood management, vascular closure, hemostasis, cell salvage, transfusion management, donor management software, sensor-guided technologies, esophageal protection, NexSys PCS, NexLynk DMS, Donor360, YES technology, Persona technology, Persona PLUS, Express Plus, Cell Saver, Cell Saver Elite, TEG 5000, TEG 6s, TEG Manager, BloodTrack, SafeTrace Tx, HaemoBank, VASCADE, VASCADE MVP, VASCADE MVP XL, SavvyWire, OptoWire, ensoETM, PerQseal Elite, MCS Mobile Apheresis System, MCS+ Mobile Platelet Collection System, ACP 215
Press page haemonetics.com/newsroom

Metrics

Valuation  
Market cap $ 5.508B
Market cap (USD) $ 5.508B
P/E 53.54
PEG —
P/BV 6.13
P/S 3.98
P/OCF 15.97
P/FCF 18.47
Dividend yield —
Turnover / mcap —
Returns  
ROE 12.0%
ROI 4.8%
ROIC 5.9%
Profit margin 7.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -5.5%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 125.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score -35.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.334B 1.361B 1.309B 1.169B 993.196M 870.463M 988.479M 967.579M 903.923M 886.116M 908.832M 910.373M 938.509M 891.99M 727.844M 676.694M 645.43M 597.879M 516.44M 449.607M 419.733M 383.598M 364.229M 336.956M 319.969M 293.86M 277.924M
Net profit 97.308M 167.679M 117.558M 115.401M 43.375M 79.469M 76.526M 55.019M 45.572M -26.268M -55.579M 16.897M 35.148M 38.8M 66.886M 79.98M 58.37M 59.304M 51.98M 49.109M 69.076M 39.639M 29.32M 28.379M 30.027M 7.236M 18.998M
Free cash flow 260.441M 142.447M 115.455M 162.867M 75.754M 71.765M 109.459M 40.32M 145.551M 83.603M 19.46M 4.958M 65.876M 22.886M 62.12M 76.786M 74.364M 59.985M 19.879M 43.125M 51.842M 53.677M 60.748M — — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 56.36 63.55 85.35 82.75 63.22 111.01 99.66 87.48 73.16 40.57 34.98 44.92 32.59 41.66 69.71 65.58 56.31 55.13 58.87 44.75 49.98 — — — — — —
Price performance 12m -0.11 -0.26 0.03 0.31 -0.43 0.11 0.14 0.2 0.8 0.16 -0.22 0.38 -0.22 -0.4 0.06 0.16 0.02 -0.06 0.32 -0.1 — — — — — — —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (USD) 153M 151M 185M 165M 128M 159M 179M 207M 203M 217M
↳ YoY growth -2.8% -1.0% +22.4% -10.7% -22.8% +24.9% +12.4% +15.3% -1.9% +7.0%
↳ 5y CAGR +2.4% -2.3% +2.4% +2.5% -4.1% +0.9% +3.4% +2.2% +4.2% +11.2%
Borrowings, current (USD) 61M 194M 27.7M 77M 17M 214M 11.8M 10.2M 304M 5.02M
Borrowings, non-current (USD) 254M 59.4M 322M 306M 691M 559M 754M 798M 921M 1.22B
Lease liabilities (USD) — — — 59.3M 70.7M 62.9M 63.1M 66.1M 58.6M 50.1M
Cash and deposits (USD) 140M 180M 169M 137M 192M 259M 284M 179M 307M 245M
Intangible assets (USD) 178M 157M 128M 133M 365M 310M 276M 406M 456M 448M
Right-of-use assets (USD) — — — 52.2M 59.9M 52.7M 53.4M 55.3M 47.5M 39.6M
Net debt (borrowings + leases - cash) (USD) 175M 73.5M 181M 305M 586M 577M 544M 695M 977M 1.03B
Cash flow detail
Operating cash flow (USD) 160M 220M 159M 158M 109M 172M 273M 182M 182M 293M
Purchases of property, plant and equipment (USD) -76.1M -74.8M -119M -48.8M -37M -96.5M -110M -66.3M -39.3M -32.8M
Change in receivables (cash effect) (USD) 3.16M 5.09M -38.1M 18.9M 44.1M -35M -24.4M -24.2M 6.96M -14.9M
Change in inventories (cash effect) (USD) -1.55M 14.4M -39.3M -84.7M -38.9M 24.3M 30.8M -60.1M -64.7M 47.4M
Change in payables (cash effect) (USD) 21.1M 41.4M 17.7M -17.3M -56.4M 7.64M 39.8M 44.6M -19.2M -16.6M
Share buybacks (cash effect) (USD) 0.00 -100M -160M -175M 0.00 0.00 -75M 0.00 -225M -175M
Interest paid (cash effect) (USD) -7.85M -7.66M -13.1M -12.5M -7.82M -6.19M -13.6M -20.9M -16.5M -17.5M
Income taxes paid (cash effect) (USD) -6.96M -9.08M -8.21M -11.5M -12.5M -24.3M -18M -52.7M -49.3M -60.7M
Share-based compensation (USD) 9.15M 13M 17.2M 20.5M 25.5M 24.4M 25.6M 28.3M 29.6M 33.8M
Operating cash flow before change in receivables (USD) 157M 215M 197M 139M 64.7M 207M 297M 206M 175M 308M
Free cash flow (OCF - PPE - intangibles) (USD) 83.6M 146M 40.3M 109M 71.8M 75.8M 163M 115M 142M 260M
Income detail
Research and development expense (USD) 37.6M 39.2M 35.7M 30.9M 32.9M 46.8M 50.1M 54.4M 62.7M 59.8M
↳ 5y CAGR +0.4% -2.4% -8.0% -10.6% -6.1% +4.5% +5.0% +8.8% +15.2% +12.7%
Total comprehensive income (USD) -24.1M 59.5M 43.6M 61.8M 95.1M 47M 111M 112M 148M 115M
Comprehensive income to owners (USD) -24.1M 59.5M 43.6M 61.8M 95.1M 47M 111M 112M 148M 115M
Provision for credit losses (USD) 11.4M 2.64M 6.33M 373,000 991,000 -359,000 -2.62M 840,000 725,000 615,000
Credit cost ratio (credit losses / average receivables) (%) 7.3% 1.7% 3.8% 0.2% 0.7% 0.3% 1.5% 0.4% 0.4% 0.3%
Reported May 24, 2017 May 23, 2018 May 22, 2019 May 20, 2020 May 26, 2021 May 25, 2022 May 22, 2023 May 20, 2024 May 21, 2025 May 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Boston, MA, November 5, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its second quarter of fiscal 2027, which ended September 26, 2026:

2nd Quarter 2027

Year-to-Date 2027

n Revenue, increase $358 million, 9%

$697 million, 8%

n Organic(1) revenue increase

10.0% 8.0%

n Earnings per diluted share $1.00 $1.72

n Adjusted earnings per diluted share $1.35 $2.49

n Cash flow from operating activities $128 million $180 million

n Free cash flow $104 million $143 million

__________

(1) Excludes the impacts of currency fluctuation and the exit of certain liquid solution products.

Chris Simon, Haemonetics’ CEO, stated: “Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities.

Nov 5, 2026

PDF Version

Financial release and supplemental presentation accessible online

BOSTON, Nov. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2027, which ended September 26, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 5, 2026.

Conference Call and Webcast Information:

  • Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event start time is recommended.

  • Live webcast: Access here or through the Investor Relations section of the Haemonetics website.

A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on November 5, 2026 and will remain accessible for one year via the webcast link above.

Earnings Materials: Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:

ABOUT HAEMONETICSHaemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:

Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 [email protected]

David Trenk, Sr. Manager-Investor Relations (203) 733-4987 [email protected]

**Media Contact:**Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-corporation-announces-second-quarter-fiscal-2027-financial-results-available-on-investor-relations-website-302930182.html

SOURCE Haemonetics Corporation

Oct 19, 2026

PDF Version

BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics' portfolio of clinically-differentiated large-bore closure devices for structural heart and endovascular procedures in the U.S., following the company's acquisition of Vivasure Medical Limited in January 2026.

The PerQseal Elite system provides sutureless, large-bore vascular closure following structural heart and endovascular procedures performed with 14 – 22F sheaths. Its fully bioabsorbable patch seals arteriotomies up to 26F from within the vessel, enabling near-instantaneous hemostasis and leaving nothing permanent behind. Physicians can confirm hemostasis while maintaining guidewire access, with the flexibility to reposition or recover the system until implant release. Results from the prospective, single-arm, multicenter ELITE arterial study demonstrated 0% major complications per VARC-3 and a mean time to hemostasis of less than one minute.1 In 2025, PerQseal Elite received CE Mark approval in Europe for both arterial and venous indications.

"FDA approval represents an important milestone in our strategy to bolster our presence and growth in advanced vascular closure, with new and meaningful innovation to meet evolving procedural needs," said Jan Hartmann, M.D., Senior Vice President and Chief Medical Officer at Haemonetics. "PerQseal Elite has the potential to further simplify minimally invasive procedures such as TAVR, while supporting patient comfort and experience. We are pleased to offer physicians and their patients in the U.S. this novel, patch-based approach to large-bore vascular closure."

Professor Nicolas van Mieghem, MD, co-investigator of the ELITE study clinical trials and interventional cardiologist at ZOL Hospital in Genk, Belgium, said, "I have found PerQseal Elite to be easy to adopt and intuitive to use, with rapid hemostasis being a particularly notable feature. In both the ELITE study and our early clinical experience, it has integrated well into procedural workflows for large-bore arterial interventions."

Clinical data related to PerQseal Elite will be presented and discussed by Haemonetics at the Transcatheter Cardiovascular Therapeutics® (TCT) Conference at the end of October.

  • VARC-3 major device-related vascular access site complications through 30 days. See PerQseal® Elite Instructions for Use.

About Haemonetics

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies designed to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.

Cautionary Statement Regarding Forward-Looking Information

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding plans and objectives of management for the operation of Haemonetics, including statements regarding potential benefits associated with the PerQseal Elite vascular closure system and Haemonetics' plans or objectives related to the commercialization of such product. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, product quality; market acceptance; the effect of economic and political conditions; and the impact of competitive products and pricing. These and other factors are identified and described in more detail in Haemonetics' periodic reports and other filings with the U.S. Securities and Exchange Commission. Haemonetics does not undertake to update these forward-looking statements.

| Investor Contacts: | |

| Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Sr. Manager-Investor Relations |

| (781) 356-9763 | (203) 733-4987 |

| [email protected] | [email protected] |

| | |

| Media Contact: | |

| Josh Gitelson, Sr. Director-Global Communications | |

| (781) 356-9776 | |

| [email protected] | |

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-announces-fda-approval-of-perqseal-elite-vascular-closure-system-302913028.html

SOURCE Haemonetics Corporation

Prompts

Haemonetics Corporation (ticker HAE), listed in United States.

ETFs Holding Haemonetics Corporation

ETF Weight in ETF Shares Market value As of
NBSM 2.08% 23,293 $ 2.401M Aug 31, 2026
JSML 1.11% 46,966 $ 4.017M Jul 31, 2026
TMAT 1.11% 30,708 $ 2.627M Jul 31, 2026
JSMD 0.91% 112,014 $ 9.582M Jul 31, 2026
LITL 0.55% 257 $ 31.076K Nov 17, 2026
MSSM 0.49% 34,111 $ 3.516M Aug 31, 2026
SIXL 0.49% 8,339 $ 1.023M Nov 12, 2026
ABCS 0.43% 522 $ 53.803K Aug 31, 2026
PSC 0.35% 110,180 $ 8.264M Jun 30, 2026
AVSC 0.34% 89,961 $ 10.916M Nov 16, 2026
SQLV 0.32% 1,231 $ 92.325K Jun 30, 2026
EHLS 0.32% 1,430 $ 173.516K Nov 17, 2026
JMEE 0.31% 73,470 $ 8.884M Nov 17, 2026
GVLU 0.30% 6,392 $ 775.605K Nov 17, 2026
FSEG 0.27% 204 $ 15.3K Jun 30, 2026
SEIS 0.17% 13,448 $ 1.009M Jun 30, 2026
MMSC 0.17% 685 $ 83.118K Nov 16, 2026
SMDX 0.16% 1,666 $ 202.152K Nov 17, 2026
RESM 0.16% 76 $ 5,700.00 Jun 30, 2026
DFAS 0.13% 343,288 $ 42.125M Nov 12, 2026
FSML 0.09% 1,453 $ 108.975K Jun 30, 2026
AVUQ 0.07% 2,486 $ 301.651K Nov 16, 2026
FSCC 0.06% 2,258 $ 232.732K Aug 31, 2026
AVSU 0.06% 2,241 $ 271.923K Nov 16, 2026
DXUV 0.05% 25,546 $ 3.135M Nov 12, 2026
AVUS 0.04% 43,952 $ 5.333M Nov 16, 2026
EBI 0.03% 2,267 $ 233.66K Aug 31, 2026
DFUV 0.03% 39,146 $ 4.804M Nov 12, 2026
DFAC 0.03% 185,553 $ 22.769M Nov 12, 2026
DFSU 0.02% 4,741 $ 581.768K Nov 12, 2026
DCOR 0.02% 79,022 $ 9.697M Nov 12, 2026
DFAU 0.01% 14,062 $ 1.726M Nov 12, 2026
DFUS 0.01% 13,353 $ 1.639M Nov 12, 2026